CORRECTION
Published on 10 Nov 2021
Corrigendum: Safety of Semaglutide
doi 10.3389/fendo.2021.786732
- 6,826 views
- 7 citations
- Frontiers in Endocrinology
- Clinical Diabetes
- Research Topics
- Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist with Both Injectable and Oral Formulations
Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist with Both Injectable and Oral Formulations
65k
Total downloads
347k
Total views and downloads
Articles
EDITORIAL
Published on 23 Sep 2021
Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
doi 10.3389/fendo.2021.760153
- 2,786 views
- 4 citations
REVIEW
Published on 07 Jul 2021
Safety of Semaglutide
doi 10.3389/fendo.2021.645563
- 313,461 views
- 173 citations
REVIEW
Published on 29 Jun 2021
Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
doi 10.3389/fendo.2021.645507
- 16,887 views
- 52 citations
REVIEW
Published on 25 Jun 2021
Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
doi 10.3389/fendo.2021.645617
- 100,696 views
- 77 citations
REVIEW
Published on 29 Mar 2021
Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
doi 10.3389/fendo.2021.645566
- 26,237 views
- 68 citations
